文献速递心律失常

β受体阻滞剂治疗儿茶酚胺敏感性多形性室速患者的结局

Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With β-Blockers.
PubMed 文献 · JAMA Cardiol · 2022-01-01

这项前瞻性队列研究纳入216例RYR2致病变异相关的CPVT患者,平均随访9.4年,发现仅用β受体阻滞剂治疗时13%发生危及生命的心律失常事件,选择性β受体阻滞剂风险高于纳多洛尔,ICD携带者事件时存活率更高。

要点

  • 选择性β受体阻滞剂较纳多洛尔增加LTAE风险约6倍。
  • 诊断前晕厥、既往LTAE和C端结构域变异提示β阻滞剂失败风险高。
  • 高危CPVT患者植入ICD与事件时死亡率降低相关。

核心结论

  • 选择性β受体阻滞剂较纳多洛尔与更高的LTAE风险相关。
  • 诊断前LTAE和晕厥以及C端结构域变异独立识别β阻滞剂治疗失败高危患者。
  • ICD与高危CPVT患者死亡率降低相关。

研究设计与样本

  • 前瞻性队列研究,1988年1月至2020年10月,意大利ICS Maugeri医院分子心脏病学门诊。
  • 纳入216例连续RYR2致病或可能致病变异携带者CPVT患者,平均(SD)随访9.4(7.5)年。

主要发现

  • 仅用β受体阻滞剂期间,28/216例(13%)发生LTAE,年发生率1.9%(95%CI 1.3-2.7)。

关键数值与推荐

  • LTAE定义为心源性猝死、复苏成功的心脏骤停和血流动力学不耐受的室性心动过速的复合终点。

临床怎么用

  • RYR2 CPVT患者β受体阻滞剂治疗宜优先选用纳多洛尔而非选择性β受体阻滞剂。
  • 对诊断前有LTAE或晕厥、携带C端结构域变异的患者应加强监测并评估ICD指征。

局限性

  • 单中心队列研究,结果外推需谨慎。
  • ICD获益分析基于事件发生时的存活比较,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with catecholaminergic polymorphic ventricular tachycardia (CPVT) may experience life-threatening arrhythmic events (LTAEs) despite β-blocker treatment. Further complicating management, the role of implantable cardioverter defibrillator (ICD) in CPVT is debated. OBJECTIVE: To investigate the long-term outcomes of patients with RYR2 CPVT treated with β-blockers only and the cost to benefit ratio of ICD. DESIGN, SETTINGS, AND PARTICIPANTS: This prospective cohort study conducted from January 1988 to October 2020 with a mean (SD) follow-up of 9.4 (7.5) years included patients who were referred to the Molecular Cardiology Clinics of ICS Maugeri Hospital, Pavia, Italy. Participants included consecutive patients with CPVT who were carriers of a pathogenic or likely pathogenic RYR2 variant with long-term clinical follow-up. EXPOSURES: Treatment with selective and nonselective β-blocker only and ICD implant when indicated. MAIN OUTCOME AND MEASURES: The main outcome was the occurrence of the first LTAE while taking a β-blocker. LTAE was defined as a composite of 3 hard end points: sudden cardiac death, aborted cardiac arrest, and hemodynamically nontolerated ventricular tachycardia. RESULTS: The cohort included 216 patients with RYR2 CPVT (121 of 216 female [55%], median [IQR] age 14, [9-30] years). During a mean (SD) follow-up of 9.4 (7.5) years taking β-blockers only, 28 of 216 patients (13%) experienced an LTAE (annual rate, 1.9%; 95% CI, 1.3-2.7). In multivariable analysis, experiencing either an LTAE (hazard ratio [HR], 3.3; 95% CI, 1.2-8.9; P = .02) or syncope before diagnosis (HR, 4.5; 95% CI, 1.8-11.1; P = .001) and carrying a C-terminal domain variant (HR, 18.1; 95% CI, 4.1-80.8; P < .001) were associated with an increased LTAE risk during β-blocker therapy only. The risk of LTAE among those taking selective β-blockers vs nadolol was increased 6-fold (HR, 5.8; 95% CI, 2.1-16.3; P = .001). Conversely, no significant difference was present between propranolol and nadolol (HR, 1.8; 95% CI, 0.4-7.3; P = .44). An ICD was implanted in 79 of 216 patients (37%) who were followed up for a mean (SD) of 8.6 (6.3) years. At the occurrence of LTAE, ICD carriers were more likely to survive (18 of 18 [100%]) than non-ICD carriers (6 of 10 [60%]; P = .01). CONCLUSIONS AND RELEVANCE: In this cohort study, selective β-blockers were associated with a higher risk of LTAE as compared with nadolol. Independently from treatment, LTAE and syncope before diagnosis and C-terminal domain variants identified patients at higher risk of β-blocker failure, and the ICD was associated with reduced mortality in high-risk patients with CPVT.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Mazzanti A, Kukavica D, Trancuccio A, et al. Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With β-Blockers. JAMA Cardiol. 2022. PMID: 35353122. doi:10.1001/jamacardio.2022.0219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。